Set Name side by side	Query	Hit Count	Set Name result set
	DB=USPT,EPAB,DWPI; PLUR=YES; OP=ADJ		
L3	('b7-1') same ('b7-2') same (antibod$) same (combine$ or combination) and(sle or lupus or autoimmun$)	43	L3
	DB=EPAB,DWPI; PLUR=YES; OP=ADJ		
L2	('b7-1') same ('b7-2') same (antibod$) and (sle or lupus)	1	L2
	DB=USPT; PLUR=YES; OP=ADJ		
L1	('b7-1') same ('b7-2') same (antibod$) and (sle or lupus)	55	L1

END OF SEARCH HISTORY

Search Results -

Term	Documents
B7-1.DWPI,EPAB,USPT.	305
B7-1S	0
B7-2.DWPI,EPAB,USPT.	292
B7-2S	0
COMBINATION.DWPI,EPAB,USPT.	1386755
COMBINATIONS.DWPI,EPAB,USPT.	373422
SLE.DWPI,EPAB,USPT.	1770
SLES.DWPI,EPAB,USPT.	167
LUPUS.DWPI,EPAB,USPT.	11160
LUPU.DWPI,EPAB,USPT.	269
ANTIBOD$	0
(('B7-1') SAME ('B7-2') SAME (ANTIBOD$) SAME (COMBINE$ OR COMBINATION) AND(SLE OR LUPUS OR AUTOIMMUN$)).USPT,EPAB,DWPI.	43

There are more results than shown above. Click here to view the entire set.

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L3

Refine Search

Recall Text | Clear

Search History

DATE: Saturday, January 18, 2003 Printable Copy Create Case

L2: Entry 5 of 10 File: USPT Jan 9, 1996

DOCUMENT-IDENTIFIER: US 5482945 A
TITLE: Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements

Detailed Description Text (5):
This invention therefore is concerned with a method of treating the diseases, syndromes, and unfavorable immunological responses which respond to treatment with rapamycin wherein the rapamycin is delivered by rapamycin-loaded formed blood elements, said rapamycin-loaded FBE being prepared extracorporeally. The following United States patents and journal articles describe the immunosuppressant, antiinflammatory, antitumor and antifungal properties of rapamycin and are herein incorporated by reference: U.S. Pat. No. 5,100,899, which discloses inhibition of transplant rejection; U.S. Pat. No. 3,993,749 which discloses antifungal properties, U.S. Pat. No. 4,885,171 which discloses antitumor activity against lymphatic leukemia, colon and mammary cancers, melanocarcinoma and ependymoblastoma; U.S. Pat. No. 4,401,653 which discloses the use of rapamycin in combination with picibanil in the treatment of tumors; U.S. Pat. No. 5,078,999 which discloses a method of treating systemic lupus erythematosus; U.S. Pat. No. 5,080,899 which discloses a method of treating pulmonary inflammation and is thus useful in the symptomatic relief of diseases in which pulmonary inflammation is a component, i.e., asthma, chronic obstructive pulmonary disease, emphysema, bronchitis, acute respiratory distress syndrome, or the like; Dumont et at., FASEB Journal 3(4), 5256 (1989) which discloses that rapamycin potentiates the suppressive activity of Cyclosporin A in T-cell proliferation, IL-2 production and IL-2R expression in mouse T-cells stimulated with ionomycin +PMA; Martel et at., Can. J. Physiol. Pharmacol. 55, 48 (1977) which discloses that rapamycin inhibits the immune response in rats in three experimental models--experimental allergic encephalomyolitis, a model for multiple sclerosis, adjuvant arthritis, a model for rheumatoid arthritis and prevents humoral (IgE-like) antibodies in response to an albumin allergic challenge; He et al., Transplantation Proceedings 24 (3), 1178 (1992) which discloses donor pretreatment with rapamycin intravenously to reduce graft rejection in rats; and R. Morris, J. Heart Lung Transplant 11(pt. 2):197(1992) where treatment with rapamycin inhibits restenosis (smooth muscle cell proliferation and internal thickening following vascular injury) which can occur after coronary angioplasty. Rapamycin is also useful in the treatment of immunoinflammatory diseases such as psoriasis.